16 October 2015 in International Journal of Clinical Pharmacy
MGMaria Victoria Gil-Navarro
Maria Victoria Gil-Navarro
+1
1 January 2025 in Journal of Diabetes Research
Aims: The study is aimed at assessing gender bias in Phase III clinical trials (CTs) of sodium–glucose cotransporter type 2 (iSGLT2) inhibitors in adults with Type 2 diabetes mellitus (T2DM). Methods: We searched PubMed and EMBASE databases until June 2023. To estimate sex bias in recruitment, the difference between F‐Particip (fraction of women recruited) and F‐Prev (prevalence fraction of women with T2DM) was calculated. A significant sex bias in recruitment was considered to exist when the difference between F‐Particip and F‐Prev was greater than 0.05, 0.1, and 0.2. The analysis was considered to have a sex bias when the efficacy variables were not analyzed by sex. Gender of the first, last, and corresponding author was also assessed. Results: In total, 70 articles met all inclusion criteria. Sex bias in recruitment showed variable results depending on the reference value. No significant sex bias in recruitment was found in the total number of included patients. Examining each CT individually, using values of significant sex bias in recruitment of ±0.05, ±0.1, or ±0.2, we found that 41.4%, 20%, and 5.7% of the trials, respectively, showed this bias. In 34.3% of the articles, women were the first, last, or corresponding authors. Sex‐based analysis of the results was performed in five studies. Conclusions: Although the proportion of women included in iSGLT2 CTs seems acceptable, gender bias persists in the analysis of variables and in the study authors. However, the lack of gender focus may be explained by the characteristics of the patients included in the CTs.
18 May 2021 in Research Square
Background Computerized clinical decision support systems are used by clinicians at the point-of-care to improve quality of healthcare processes (prescribing error prevention, adherence to clinical guidelines...) and clinical outcomes (preventive, therapeutic, and diagnostics). Attempts to summarize results of computerized clinical decision support systems to support prescription in primary care have been challenging, and most systematic reviews and meta-analyses failed due to an extremely high degree of heterogeneity present among the included primary studies. The aim of our study will be to synthesize the evidence, considering all methodological factors that could explain these differences, and to build an evidence and gap map to identify important remaining research questions. Methods A literature search will be conducted from January 2010 onwards in Medline, Embase, The Cochrane Library and Web of Science databases. Two reviewers will independently screen all citations, full-text and abstract data. The study methodological quality and risk of bias will be appraised using appropriate tools if applicable. A flow diagram with the screened studies will be presented, and all included studies will be displayed using interactive evidence and gap maps. Results will be reported in accordance with recommendations from The Campbell Collaboration on the development of evidence and gap maps. Discussion Evidence behind computerized clinical decision support systems to support prescription use in primary care, has so far been difficult to be synthesized. Evidence and gap maps represent an innovative approach that has emerged and is increasingly being used to address a broader research question, where multiple types of intervention and outcomes reported may be evaluated. Broad inclusion criteria have been chosen with regards to study designs, in order to collect all available information. Regarding the limitations we will only include English and Spanish language studies from the last 10 years, we will not perform a grey literature search, and we will not carry out a meta-analysis due to the predictable heterogeneity of available studies. Systematic Review registration: This study is registered in Open Science Framework https://bit.ly/2RqKrWp